CytomX Therapeutics enters a pivotal week with a headline-grabbing Regeneron collaboration pulling in one direction and a 14% stock decline pulling hard in the other.
CytomX announced an expansion of its strategic research collaboration with Regeneron on June 3, targeting conditional bispecific therapeutics for cancer treatment in a deal framed at $4 billion in potential value. The news arrived as the stock was already down 14% on the week and 24% over the past month — closing at $3.16 on June 2, its lowest point in recent memory. The contrast is sharp: a transformational partnership on the press wire, a stock that has been punished heavily in the weeks leading up to it.
Short sellers have been steadily building their position through May, and that positioning is now the story's sharpest edge. Short interest has climbed from around 11% of the free float in late April to 16.7% as of June 2 — a near-50% increase in six weeks. The broader snapshot from the data_snapshot suggests 18.3% against total float, placing bears in a genuinely material position. Yet the borrow market offers no sense of urgency. Cost to borrow is running at just 0.43% annually — near its lowest level of the past two months. And availability is exceptionally loose at 650%, meaning there are roughly six and a half times more shares available to borrow than are currently shorted. Squeezable this setup is not. Short sellers face no meaningful funding pressure, and the mechanics of any reversal would have to come from covering on fundamental news rather than from a borrow crunch.
Options paint a more bullish picture than the shorts suggest. The put/call ratio has dropped sharply to 0.35, well below its 20-day average of 0.52 — almost a full standard deviation light on hedging demand. That compares to readings consistently above 0.75 throughout April and early May. Options traders have rotated away from downside protection at speed: the 52-week high on PCR is 1.38, making the current reading about as call-heavy as this stock gets. If the Regeneron announcement catalyses fresh institutional interest, the options market is already set up for it.
The Street remains broadly constructive, though targets have come down. Seven analysts carry Buy or equivalent ratings, with a mean price target of $12.30 against a $3.16 close — a gap that is large enough to be structurally interesting but that must be read carefully given how recently targets have moved. HC Wainwright cut its target to $11 from $17 on May 11, shortly after Q1 earnings. Earlier in March, a cluster of upgrades and target raises — from Barclays, Jefferies, Guggenheim, and JP Morgan — pushed consensus higher when the stock was above $6. JP Morgan's upgrade to Overweight from Neutral in mid-March, with a $12 target, was the bellwether move. Since then, the stock has halved. The EPS momentum factor scores are stronger than the price action implies — ranking in the 81st percentile on 30-day EPS momentum and 85th on 90-day — while the analyst recommendation divergence score registers in the 97th percentile, indicating the Street is far more positive than price-based signals would predict. Wolfe Research initiated coverage with an Outperform rating as recently as May 22, adding another voice to the buy camp ahead of earnings.
The insider picture is one-directional. In March, four executives sold simultaneously — including CEO Sean McCarthy, CFO Christopher Ogden, the CMO, and the Chief Scientific Officer — at prices around $6.42. Net insider selling over the 90 days through March 17 totalled roughly $1.2 million in value. These were likely pre-arranged 10b5-1 plan sales, but the timing, coming just as analyst targets were being raised, is a pattern worth noting. There has been no insider buying on record.
Earnings are due June 17. The last two prints produced consistent negative reactions: a 3.5% one-day decline in early May and a 3.6% decline the prior quarter, with five-day losses of 9-10% in both cases. The Regeneron deal, announced two weeks before the print, changes the narrative context materially — whether that shifts the post-earnings pattern is the central question heading into the date. What to watch is whether the collaboration announcement generates institutional follow-through before June 17, or whether the earnings reaction template reasserts itself in the absence of new clinical data.
See the live data behind this article on ORTEX.
Open CTMX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
